Target intelligence / Profile preview

Multidrug resistance-associated protein 2 (MRP2)

Target
MRP2
Molecular classification
Transporter, ATP-binding cassette transporter
01

Overview

Multidrug resistance-associated protein 2 (MRP2), encoded by the ABCC2 gene, is an ATP-dependent efflux transporter primarily localized to the apical (canalicular) membrane of hepatocytes, as well as the apical membranes of renal proximal tubule cells, enterocytes, and syncytiotrophoblasts of the placenta. It plays a critical physiological role in detoxification and tissue protection by mediating the active transport of endogenous substances, such as conjugated bilirubin, sulfated bile salts, and leukotrienes, into bile, urine, or the intestinal lumen. In addition to endogenous metabolites, MRP2 transports a wide variety of xenobiotics and therapeutic drugs, including chemotherapeutic agents (e.g., cisplatin, methotrexate, irinotecan), antivirals, and antibiotics. Overexpression of MRP2 in cancer cells is a major driver of multidrug resistance (MDR), leading to reduced intracellular drug accumulation and chemotherapy failure. Conversely, genetic mutations in ABCC2 cause Dubin-Johnson syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia. Pharmacological inhibition or modulation of MRP2 can lead to significant drug-drug interactions (DDIs) and toxicities, such as drug-induced liver injury or iatrogenic Fanconi syndrome, making it a key target of interest in pharmacokinetics, toxicology, and oncology.

Other names
ATP-binding cassette sub-family C member 2ABCC2Canalicular multispecific organic anion transporter 1cMOATCanalicular multidrug resistance proteinDJScMRP
02

Mechanism of action

Drugs target MRP2 either as substrates that are actively effluxed from the cell via ATP hydrolysis, or as inhibitors/modulators that block the transporter's binding pocket to prevent efflux of other drugs, thereby reversing multidrug resistance or causing drug-drug interactions.

03

Biological functions

Active transportEffluxDetoxificationBiliary excretionDrug dispositionXenobiotic transport
04

Disease associations

CancerMultidrug resistanceDubin-Johnson syndromeDrug-induced liver injuryCholestasisFanconi syndrome
05

Safety considerations

Drug-drug interactions (DDIs)HepatotoxicityHyperbilirubinemiaNephrotoxicity (e.g., Fanconi syndrome)Chemoresistance / Multidrug resistance in cancer therapy
06

Interacting drugs

15 more in the full profile.

07

Biomarkers

Coproporphyrin ICoproporphyrin IIIUrinary coproporphyrin ratio (UCP I/(I + III))Bilirubin levelsABCC2 gene polymorphisms

Beyond the preview

Go deeper on Multidrug resistance-associated protein 2 (MRP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multidrug resistance-associated protein 2 (MRP2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call